PRICE T ROWE ASSOCIATES INC /MD/ - ARBUTUS BIOPHARMA CORP ownership

ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 97 filers reported holding ARBUTUS BIOPHARMA CORP in Q3 2023. The put-call ratio across all filers is 0.90 and the average weighting 0.2%.

Quarter-by-quarter ownership
PRICE T ROWE ASSOCIATES INC /MD/ ownership history of ARBUTUS BIOPHARMA CORP
ValueSharesWeighting
Q3 2023$55
-6.8%
26,735
+4.3%
0.00%
Q2 2023$59
-10.6%
25,629
+19.2%
0.00%
Q1 2023$66
+40.4%
21,495
+7.2%
0.00%
Q4 2022$47
-99.9%
20,049
+10.9%
0.00%
Q3 2022$35,000
+29.6%
18,075
+79.3%
0.00%
Q2 2022$27,000
-99.4%
10,083
-98.0%
0.00%
-100.0%
Q3 2018$4,700,000497,3280.00%
Other shareholders
ARBUTUS BIOPHARMA CORP shareholders Q3 2023
NameSharesValueWeighting ↓
JACOB ASSET MANAGEMENT OF NEW YORK LLC 340,000$1,459,0000.53%
RTW INVESTMENTS, LP 4,733,323$20,306,0000.31%
APIS CAPITAL ADVISORS, LLC 70,000$300,0000.29%
Hudson Bay Capital Management LP 1,800,000$7,722,0000.10%
COWEN AND COMPANY, LLC 249,215$1,069,0000.05%
Kerrisdale Advisers, LLC 100,000$429,0000.05%
Woodline Partners LP 496,172$2,129,0000.04%
Shay Capital LLC 60,000$257,0000.03%
Walleye Capital LLC 231,037$991,0000.03%
BOOTHBAY FUND MANAGEMENT, LLC 212,700$912,0000.02%
View complete list of ARBUTUS BIOPHARMA CORP shareholders